Loading...
The industry-funded European Active Surveillance Study did not show drospirenone to be associated with excess thromboembolic risk, but a number of large epidemiologic studies have raised concern that drospirenone-containing contraceptives might be more commonly associated with thromboembolic events than are combined hormonal contraceptives containing levonorgestrel or norethindrone. By combining records from four demographically diverse U.S. health plans, investigators identified data from 573,680 new contraceptive users, who experienced 321 venous thromboembolic events (VTEs) during 367,138 woman-years of exposure from 2001 through 2007.
Although absolute risk for a VTE among drospirenone users was low (1.4 per 1000 woman-years), in models …